BCL6 inhibitors
US11512095B2 · kind B2 · utility
2Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 12, 2019 |
| Grant date | Nov 29, 2022 |
| Priority date | — |
| Expiry date | Jun 17, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.